Neptune Technologies patent granted for novel phospholipids
in multiple diseases and pharmaceutical applications
---Composition of Matter Patent Granted and Enforceable in 24 European Countries---
--- Competitors Precluded from Immediate Commercialization of Competitive Products ---
Laval, Québec, CANADA - March 27 th , 2008 - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT -
TSX.V.NTB) announces that the European Patent Office (EPO) granted on May 31 st 2007 Neptune's composition of matter
patent entitled "Natural Marine Source Phospholipids comprising flavonoïds, polyunsaturated fatty acids and their
applications" (EP01417211B1) and that this patent has now been issued and validated in twenty-four European countries.
This patent is directed to the use of Neptune marine phospholipid and flavonoïd compositions as a medicament for the
prevention and treatment of multiple chronic health conditions, including coronary artery disease caused by
hypercholesterolemia, peripheral vascular disease, neurodegenerative and other cognitive disorders.
"This composition of matter patent is a critical achievement that constitutes a key component for our commercial pharmaceutical
development program," said Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "Neptune's mission has always been the
development of innovative pharmaceutical ingredients, and this patent is viewed as a vital element towards Neptune's
pharmaceutical initiatives. Its enforcement is a major accomplishment and a step forward," she added.
As part of the EPO procedure, within a nine-month period following the date of granting of the European patent, a notice of
opposition can be filed in writing with the EPO. In the case of Neptune, oppositions were filed by Norway-based Aker
BioMarine and Israel-based Enzymotec. The opposition proceedings are a multi-year (5-7 year) procedure with the potential
outcome of maintaining the patent, amending it or, in certain cases, revoking it. According to EPO